Health care stocks were edging higher pre-bell Tuesday, with the iShares Biotechnology ETF (IBB) and The Health Care Select Sector SPDR Fund (XLV) up 0.1%.
Apellis Pharmaceuticals (APLS) shares were down more than 2% even after the company said Australia's Therapeutic Goods Administration approved Syfovre for the every-other-month treatment of geographic atrophy in adults with age-related macular degeneration resulting in vision loss.
Akero Therapeutics (AKRO) stock was nearly 5% higher after the company said it has started an underwritten public offering of $300 million of shares, with J.P. Morgan, Morgan Stanley and Jefferies as book-running managers.
AstraZeneca (AZN) shares were marginally higher after the company and Daiichi Sankyo said their drug Enhertu has been approved in the US for the treatment of adult patients with certain types of inoperable breast cancer that has progressed on one or more endocrine therapies.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。